Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

被引：0
|
作者：
Jean Claude Alvarez
Pierre Moine
Benjamin Davido
Isabelle Etting
Djillali Annane
Islam Amine Larabi
Nicolas Simon
机构：
[1] Raymond Poincaré Hospital,Department of Pharmacology and Toxicology, Paris
[2] AP-HP,Saclay University (Versailles Saint
[3] Hôpital Raymond Poincaré,Quentin
[4] AP-HP,en
[5] Raymond Poincaré hospital,Yvelines), Inserm U
[6] AP-HP,1173, FHU Sepsis
[7] Raymond Poincaré hospital,Laboratoire de Pharmacologie
[8] AP-HP,Toxicologie, Université de Versailles Saint
[9] Aix-Marseille University,Quentin
来源：
European Journal of Clinical Pharmacology | 2021年 / 77卷
关键词：
Lopinavir; Pharmacokinetics; Covid-19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：389 / 397
页数：8
相关论文
共 50 条
  • [11] Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 Patients
    Chouchana, Laurent
    Boujaafar, Sana
    Gana, Ines
    Preta, Laure-Helene
    Regard, Lucile
    Legendre, Paul
    Azoulay, Celia
    Canoui, Etienne
    Zerbit, Jeremie
    Carlier, Nicolas
    Terrier, Benjamin
    Kerneis, Solen
    Batista, Rui
    Treluyer, Jean-Marc
    Zheng, Yi
    Benaboud, Sihem
    THERAPEUTIC DRUG MONITORING, 2021, 43 (01) : 131 - 135
  • [12] Lopinavir/ritonavir delays COVID-19 recovery in paediatric patients
    Reactions Weekly, 2022, 1903 (1) : 8 - 8
  • [13] SARS-CoV-2 viral dynamics and population pharmacokinetics of favipiravir in combination with lopinavir-ritonavir in patients with COVID-19
    Agyeman, Akosua A.
    Brown, Li-An K.
    Guerra-Assuncao, Jose A.
    Breuer, Judy
    Lowe, David M.
    Standing, Joseph F.
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 291 - 294
  • [14] A Trial of Lopinavir-Ritonavir in Covid-19
    Carmona-Bayonas, Alberto
    Jimenez-Fonseca, Paula
    Castanon, Eduardo
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21):
  • [15] Lopinavir-ritonavir in severe COVID-19
    Stower, Hannah
    NATURE MEDICINE, 2020, 26 (04) : 465 - 465
  • [16] Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
    Mohsenian Naghani, Shaghayegh
    Jansen, Mark M. P. M.
    Jaspers, Tessa
    Bastiaans, Diane
    Burger, David
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (E1) : E106 - E108
  • [17] Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir
    Mas Serrano, Miguel
    Ricardo Perez-Sanchez, Javier
    Portela Sanchez, Sofia
    De la Casa-Fages, Beatriz
    Mato Jimeno, Victor
    Perez Tamayo, Isabel
    Grandas, Francisco
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2020, 415
  • [18] Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19
    Vecchio, Gisela
    Zapico, Valeria
    Catanzariti, Alejandro
    Carboni Bisso, Indalecio
    Las Heras, Marcos
    MEDICINA-BUENOS AIRES, 2020, 80 (05) : 439 - 441
  • [19] Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
    Baldelli, Sara
    Corbellino, Mario
    Clementi, Emilio
    Cattaneo, Dario
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2704 - 2706
  • [20] A Trial of Lopinavir-Ritonavir in Covid-19 Reply
    Cao, Bin
    Zhang, Dingyu
    Wang, Chen
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21):
12345